At a glance
ClinicalIndex Comparison Record- ✓Pathologically confirmed (histologic or cytologic) NSCLC
- ✓Stage IIIB with malignant pleural effusion or Stage IV disease
- ✓At least one measurable or evaluable NSCLC lesion (not previously irradiated, or if irradiated >3 weeks prior with documented progression)
- ✓Adequate organ system function
- ✕Brain metastasis
- ✕Prior chemotherapy for NSCLC
- ✕Prior platinum-based chemotherapy for any indication
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Phase III Trial Comparing Targretin Capsules/Carboplatin/Paclitaxel Versus Carboplatin/Paclitaxel in Chemotherapy-Naïve Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
In Brief
A Phase 3 clinical trial evaluating bexarotene with carboplatin and paclitaxel and carboplatin and paclitaxel for Non-small Cell Lung Cancer. Completed, enrolled 612 participants across 154 sites in 6 countries.
Detailed Summary
This study evaluates the use of Targretin capsules (bexarotene) in combination with standard chemotherapy for the treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) in patients who have not yet received chemotherapy for their lung cancer.
Study Details
Timeline
Interventions
bexarotene capsules (400 mg/m\^2/day) in combination with carboplatin IV (AUC 6) every 3 weeks and paclitaxel IV (200 mg/m\^2) every 3 weeks. Subjects in this group also received an antilipid agent which was selected at the discretion of the investigator.
carboplatin IV (AUC 6) every 3 weeks and paclitaxel IV (200 mg/m\^2) every 3 weeks.